CUDC-101

DRUG4 trials

Sponsors

Curis, Inc.

Conditions

Breast CancerCancerGastric CancerHead and Neck CancerLiver CancerNon-Small Cell Lung CancerTumors

Phase 1

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

CompletedNCT00728793

Curis, Inc.Tumors

Start: 2008-08-31End: 2010-04-30Updated: 2018-02-22

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

CompletedNCT01171924

Curis, Inc.Breast Cancer, Gastric Cancer, Head and Neck Cancer +2

Start: 2010-07-31End: 2011-10-31Updated: 2016-03-01

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

CompletedNCT01384799

Curis, Inc.Head and Neck Cancer

Start: 2011-11-30End: 2013-10-31Updated: 2018-02-22

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

TerminatedNCT01702285

Curis, Inc.Cancer

Start: 2012-09-30End: 2012-12-31Updated: 2018-02-12